A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

NCT01021358 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Lymphoma
Chronic Lymphocytic Leukemia
Solid Tumors

Interventions

DRUG: ABT-263
DRUG: Ketoconazole

Sponsor

Abbott